Sanofi’s Enjaymo, the only approved drug therapy for a rare and debilitating blood disorder, is being acquired by Recordati in a deal that helps the Italian company build its rare disease ...

Oct 4 (Reuters) - Italian pharma group Recordati (RECI.MI), opens new tab said on Friday it would buy from Sanofi (SASY.PA), opens new tab the global rights to a drug used to treat cold agglutinin ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. Recordati is floating $825 million upfront—plus another $250 million in potential commercial ...

Metoprolol is a beta-blocker approved by the Food and Drug Administration (FDA) to treat several cardiovascular conditions, ...

Metoprolol is a beta-blocker that affects the heart and circulation (blood flow through arteries and veins). Metoprolol is used to treat angina (chest pain) and hypertension (high blood pressure).

A pharmacist explains the similarities and differences between these two heart medications Atenolol (brand name Tenormin) and ...

Recordati will acquire global rights to Enjaymo for $825M upfront and up to $250M in milestone payments. Enjaymo generated €100M in revenue in 2024 and is expected to exceed €150M in 2025 ...

Recordati reached an agreement with French pharmaceutical company Sanofi to acquire the global rights to autoimmune disorder treatment Enjaymo for $825 million. The Italian pharmaceutical company ...

Maack et al. [70] recently reported on switching between β blockers (metoprolol and carvedilol) in 68 patients treated with either agent for 1 year who had improved in terms of LVEF and NYHA class.

Milan, 4 th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for ...

(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 ...